{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:32:12Z","timestamp":1791570732437,"version":"4.3.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R44NS102398"],"award-info":[{"award-number":["R44NS102398"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R41NS094327"],"award-info":[{"award-number":["R41NS094327"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021976","name":"Medical Technology Enterprise Consortium","doi-asserted-by":"publisher","award":["W81XWH-21-9-0001"],"award-info":[{"award-number":["W81XWH-21-9-0001"]}],"id":[{"id":"10.13039\/100021976","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["ZIADK031117"],"award-info":[{"award-number":["ZIADK031117"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Purinergic Signalling"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s11302-026-10161-7","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:04:26Z","timestamp":1778583866000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The long march towards testing the adenosine receptor agonism hypothesis for human cerebroprotection: The story of the A1R\/A3R receptor agonist AST-004"],"prefix":"10.1007","volume":"22","author":[{"given":"Theodore E.","family":"Liston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Korinek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Lechleiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"issue":"2","key":"10161_CR1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1177\/17474930241308142","volume":"20","author":"VL Feigin","year":"2025","unstructured":"Feigin VL, Brainin M, Norrving B, Martins SO, Pandian J, Lindsay P, Fg M, Rautalin I (2025) World Stroke Organization: global stroke fact sheet 2025. Int J Stroke 20(2):132\u2013144. https:\/\/doi.org\/10.1177\/17474930241308142","journal-title":"Int J Stroke"},{"issue":"10","key":"10161_CR2","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.apmr.2015.07.001","volume":"96","author":"SR Flanagan","year":"2015","unstructured":"Flanagan SR (2015) Invited commentary on \u201cCenters for Disease Control and Prevention report to Congress: traumatic brain injury in the United States: epidemiology and rehabilitation.\u201d Arch Phys Med Rehabil 96(10):1753\u20131755. https:\/\/doi.org\/10.1016\/j.apmr.2015.07.001","journal-title":"Arch Phys Med Rehabil"},{"issue":"10","key":"10161_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-075049","volume":"13","author":"B Guan","year":"2023","unstructured":"Guan B, Anderson DB, Chen L, Feng S, Zhou H (2023) Global, regional and national burden of traumatic brain injury and spinal cord injury, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. BMJ Open 13(10):e075049. https:\/\/doi.org\/10.1136\/bmjopen-2023-075049","journal-title":"BMJ Open"},{"issue":"10029","key":"10161_CR4","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/S0140-6736(16)00163-X","volume":"387","author":"M Goyal","year":"2016","unstructured":"Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, Davalos A, Majoie CB, van der Lugt A, de Miquel MA, Donnan GA, Roos YB, Bonafe A, Jahan R, Diener HC, van den Berg LA, Levy EI, Berkhemer OA, Pereira VM, Rempel J, Millan M, Davis SM, Roy D, Thornton J, Roman LS, Ribo M, Beumer D, Stouch B, Brown S, Campbell BC, van Oostenbrugge RJ, Saver JL, Hill MD, Jovin TG, Dippel DWJ, Majoie CBLM, Roos YBWEM, Campbell BCV (2016) Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 387(10029):1723\u20131731. https:\/\/doi.org\/10.1016\/S0140-6736(16)00163-X","journal-title":"Lancet"},{"issue":"11","key":"10161_CR5","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1097\/CCM.0000000000004597","volume":"48","author":"F Herpich","year":"2020","unstructured":"Herpich F, Rincon F (2020) Management of acute ischemic stroke. Crit Care Med 48(11):1654\u20131663. https:\/\/doi.org\/10.1097\/CCM.0000000000004597","journal-title":"Crit Care Med"},{"issue":"3","key":"10161_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMcp1917030","volume":"383","author":"WJ Powers","year":"2020","unstructured":"Powers WJ (2020) Acute ischemic stroke. N Engl J Med 383(3):252\u2013260. https:\/\/doi.org\/10.1056\/NEJMcp1917030","journal-title":"N Engl J Med"},{"key":"10161_CR7","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041353","author":"MB Ahrens","year":"2024","unstructured":"Ahrens MB, Khakh BS, Poskanzer KE (2024) Astrocyte calcium signaling. Cold Spring Harb Perspect Biol. https:\/\/doi.org\/10.1101\/cshperspect.a041353","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"11","key":"10161_CR8","doi-asserted-by":"publisher","first-page":"14947","DOI":"10.1007\/s12035-025-05055-5","volume":"62","author":"X Li","year":"2025","unstructured":"Li X, Ding L, Nie H, Deng DYB (2025) Calcium signaling in astrocytes and its role in the central nervous system injury. Mol Neurobiol 62(11):14947\u201314965. https:\/\/doi.org\/10.1007\/s12035-025-05055-5","journal-title":"Mol Neurobiol"},{"key":"10161_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/978-981-13-9913-8_3","volume":"1175","author":"A Verkhratsky","year":"2019","unstructured":"Verkhratsky A, Parpura V, Vardjan N, Zorec R (2019) Physiology of astroglia. Adv Exp Med Biol 1175:45\u201391. https:\/\/doi.org\/10.1007\/978-981-13-9913-8_3","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"10161_CR10","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.neuron.2015.03.035","volume":"86","author":"PJ Magistretti","year":"2015","unstructured":"Magistretti PJ, Allaman I (2015) A cellular perspective on brain energy metabolism and functional imaging. Neuron 86(4):883\u2013901. https:\/\/doi.org\/10.1016\/j.neuron.2015.03.035","journal-title":"Neuron"},{"issue":"1387","key":"10161_CR11","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1098\/rstb.1999.0471","volume":"354","author":"PJ Magistretti","year":"1999","unstructured":"Magistretti PJ, Pellerin L (1999) Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Philos Trans R Soc Lond B Biol Sci 354(1387):1155\u20131163","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"10","key":"10161_CR12","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/glia.20996","volume":"58","author":"ND Halim","year":"2010","unstructured":"Halim ND, McFate T, Mohyeldin A, Okagaki P, Korotchkina LG, Patel MS, Jeoung NH, Harris RA, Schell MJ, Verma A (2010) Phosphorylation status of pyruvate dehydrogenase distinguishes metabolic phenotypes of cultured rat brain astrocytes and neurons. Glia 58(10):1168\u20131176. https:\/\/doi.org\/10.1002\/glia.20996","journal-title":"Glia"},{"issue":"24","key":"10161_CR13","doi-asserted-by":"publisher","first-page":"6510","DOI":"10.1523\/JNEUROSCI.1256-07.2007","volume":"27","author":"J Wu","year":"2007","unstructured":"Wu J, Holstein JD, Upadhyay G, Lin DT, Conway S, Muller E, Lechleiter JD (2007) Purinergic receptor-stimulated IP3-mediated Ca2+ release enhances neuroprotection by increasing astrocyte mitochondrial metabolism during aging. J Neurosci 27(24):6510\u20136520. https:\/\/doi.org\/10.1523\/JNEUROSCI.1256-07.2007","journal-title":"J Neurosci"},{"key":"10161_CR14","doi-asserted-by":"publisher","unstructured":"Fisher ES, Chen Y, Sifuentes MM, Stubblefield JJ, Lozano D, Holstein DM, Ren J, Davenport M, DeRosa N, Chen T-p, Nickel G, Liston TE and Lechleiter JD (2022) Adenosine A1R\/A3R agonist AST-004 reduces brain infarction in mouse and rat models of acute ischemic stroke. Frontiers in Stroke 1. https:\/\/doi.org\/10.3389\/fstro.2022.1010928","DOI":"10.3389\/fstro.2022.1010928"},{"issue":"4","key":"10161_CR15","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/jcbfm.2012.214","volume":"33","author":"W Zheng","year":"2013","unstructured":"Zheng W, Talley Watts L, Holstein DM, Wewer J, Lechleiter JD (2013) P2Y1R-initiated, IP3R-dependent stimulation of astrocyte mitochondrial metabolism reduces and partially reverses ischemic neuronal damage in mouse. J Cereb Blood Flow Metab 33(4):600\u2013611. https:\/\/doi.org\/10.1038\/jcbfm.2012.214","journal-title":"J Cereb Blood Flow Metab"},{"issue":"12","key":"10161_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014401","volume":"5","author":"W Zheng","year":"2010","unstructured":"Zheng W, Watts LT, Holstein DM, Prajapati SI, Keller C, Grass EH, Walter CA, Lechleiter JD (2010) Purinergic receptor stimulation reduces cytotoxic edema and brain infarcts in mouse induced by photothrombosis by energizing glial mitochondria. PLoS One 5(12):e14401. https:\/\/doi.org\/10.1371\/journal.pone.0014401","journal-title":"PLoS One"},{"issue":"5","key":"10161_CR17","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.bbabio.2009.02.021","volume":"1787","author":"F Celsi","year":"2009","unstructured":"Celsi F, Pizzo P, Brini M, Leo S, Fotino C, Pinton P, Rizzuto R (2009) Mitochondria, calcium and cell death: a deadly triad in neurodegeneration. Biochim Biophys Acta 1787(5):335\u2013344. https:\/\/doi.org\/10.1016\/j.bbabio.2009.02.021","journal-title":"Biochim Biophys Acta"},{"issue":"50","key":"10161_CR18","doi-asserted-by":"publisher","first-page":"6407","DOI":"10.1038\/onc.2008.308","volume":"27","author":"P Pinton","year":"2008","unstructured":"Pinton P, Giorgi C, Siviero R, Zecchini E, Rizzuto R (2008) Calcium and apoptosis: ER-mitochondria Ca2+ transfer in the control of apoptosis. Oncogene 27(50):6407\u20136418. https:\/\/doi.org\/10.1038\/onc.2008.308","journal-title":"Oncogene"},{"issue":"11","key":"10161_CR19","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/j.bbabio.2009.05.011","volume":"1787","author":"RS Balaban","year":"2009","unstructured":"Balaban RS (2009) The role of Ca2+ signaling in the coordination of mitochondrial ATP production with cardiac work. Biochim Biophys Acta 1787(11):1334\u20131341. https:\/\/doi.org\/10.1016\/j.bbabio.2009.05.011","journal-title":"Biochim Biophys Acta"},{"key":"10161_CR20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.yjmcc.2012.12.021","volume":"58","author":"EN Dedkova","year":"2013","unstructured":"Dedkova EN, Blatter LA (2013) Calcium signaling in cardiac mitochondria. J Mol Cell Cardiol 58:125\u2013133. https:\/\/doi.org\/10.1016\/j.yjmcc.2012.12.021","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"10161_CR21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ceca.2012.03.003","volume":"52","author":"AI Tarasov","year":"2012","unstructured":"Tarasov AI, Griffiths EJ, Rutter GA (2012) Regulation of ATP production by mitochondrial Ca2+. Cell Calcium 52(1):28\u201335. https:\/\/doi.org\/10.1016\/j.ceca.2012.03.003","journal-title":"Cell Calcium"},{"issue":"4","key":"10161_CR22","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1007\/s13311-021-01113-7","volume":"18","author":"E Bozdemir","year":"2021","unstructured":"Bozdemir E, Vigil FA, Chun SH, Espinoza L, Bugay V, Khoury SM, Holstein DM, Stoja A, Lozano D, Tunca C, Sprague SM, Cavazos JE, Brenner R, Liston TE, Shapiro MS, Lechleiter JD (2021) Neuroprotective roles of the adenosine A3 receptor agonist AST-004 in mouse model of traumatic brain injury. Neurotherapeutics 18(4):2707\u20132721. https:\/\/doi.org\/10.1007\/s13311-021-01113-7","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10161_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1089\/neu.2012.2488","volume":"30","author":"L Talley Watts","year":"2013","unstructured":"Talley Watts L, Sprague S, Zheng W, Garling RJ, Jimenez D, Digicaylioglu M, Lechleiter J (2013) Purinergic 2Y1 receptor stimulation decreases cerebral edema and reactive gliosis in a traumatic brain injury model. J Neurotrauma 30(1):55\u201366. https:\/\/doi.org\/10.1089\/neu.2012.2488","journal-title":"J Neurotrauma"},{"issue":"4","key":"10161_CR24","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s11302-020-09732-z","volume":"16","author":"TE Liston","year":"2020","unstructured":"Liston TE, Hinz S, Muller CE, Holstein DM, Wendling J, Melton RJ, Campbell M, Korinek WS, Suresh RR, Sethre-Hofstad DA, Gao ZG, Tosh DK, Jacobson KA, Lechleiter JD (2020) Nucleotide P2Y1 receptor agonists are in vitro and in vivo prodrugs of A1\/A3 adenosine receptor agonists: implications for roles of P2Y1 and A1\/A3 receptors in physiology and pathology. Purinergic Signal 16(4):543\u2013559. https:\/\/doi.org\/10.1007\/s11302-020-09732-z","journal-title":"Purinergic Signal"},{"issue":"1\u20134","key":"10161_CR25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3109\/10799899909036663","volume":"19","author":"GG Yegutkin","year":"1999","unstructured":"Yegutkin GG, Burnstock G (1999) Steady-state binding of adenine nucleotides ATP, ADP and AMP to rat liver and adipose plasma membranes. J Recept Signal Transduct Res 19(1\u20134):437\u2013448. https:\/\/doi.org\/10.3109\/10799899909036663","journal-title":"J Recept Signal Transduct Res"},{"key":"10161_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1146\/annurev.neuro.24.1.31","volume":"24","author":"TV Dunwiddie","year":"2001","unstructured":"Dunwiddie TV, Masino SA (2001) The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 24:31\u201355. https:\/\/doi.org\/10.1146\/annurev.neuro.24.1.31","journal-title":"Annu Rev Neurosci"},{"key":"10161_CR27","unstructured":"Bozdemir E, Vigil FA, Bugay V, Chun SH, Espinoza L, Lorenzo D, Holstein DM, Elliot R, Sprague C, Rule G, Cavazos JE, Shapiro MS, Zamora D, Brenner R, Lechleiter JD (2019) Protective Role of ADORA3 Agonist AST-004 in Blast and Blunt TBI Models, in Military Health System Research Symposium: KIssimmee, FL. USA.  Abstract MHSRS-19-01783"},{"issue":"13","key":"10161_CR28","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2019.29100.abstracts","volume":"36","author":"T Kilbaugh","year":"2019","unstructured":"Kilbaugh T, Liston T, Stolow M, Hanlon L, Bozdemir E, Holstein D, Kurbanov A, Tunca C, Poe R, Lorenzo D, Sethre-Hofstad D, Lechleiter J, Margulies S (2019) Protective role of AST-004 in piglet model of blunt TBI - abstract. J Neurotrauma 36(13):10384. https:\/\/doi.org\/10.1089\/neu.2019.29100.abstracts","journal-title":"J Neurotrauma"},{"issue":"1","key":"10161_CR29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1161\/strokeaha.121.036396","volume":"53","author":"TE Liston","year":"2022","unstructured":"Liston TE, Hama A, Boltze J, Poe RB, Natsume T, Hayashi I, Takamatsu H, Korinek WS, Lechleiter JD (2022) Adenosine A1R\/A3R (adenosine A1 and A3 receptor) agonist AST-004 reduces brain infarction in a nonhuman primate model of stroke. Stroke 53(1):238\u2013248. https:\/\/doi.org\/10.1161\/strokeaha.121.036396","journal-title":"Stroke"},{"key":"10161_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1749-6632.1997.tb48411.x","volume":"825","author":"N Bischofberger","year":"1997","unstructured":"Bischofberger N, Jacobson KA, von Lubitz DK (1997) Adenosine A1 receptor agonists as clinically viable agents for treatment of ischemic brain disorders. Ann N Y Acad Sci 825:23\u201329. https:\/\/doi.org\/10.1111\/j.1749-6632.1997.tb48411.x","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"10161_CR31","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1124\/dmd.109.026674","volume":"37","author":"X Liu","year":"2009","unstructured":"Liu X, Vilenski O, Kwan J, Apparsundaram S, Weikert R (2009) Unbound brain concentration determines receptor occupancy: a correlation of drug concentration and brain serotonin and dopamine reuptake transporter occupancy for eighteen compounds in rats. Drug Metab Dispos 37(7):1548\u20131556. https:\/\/doi.org\/10.1124\/dmd.109.026674","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10161_CR32","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1161\/STROKEAHA.111.618801","volume":"42","author":"BT Bratane","year":"2011","unstructured":"Bratane BT, Cui H, Cook DJ, Bouley J, Tymianski M, Fisher M (2011) Neuroprotection by freezing ischemic penumbra evolution without cerebral blood flow augmentation with a postsynaptic density-95 protein inhibitor. Stroke 42(11):3265\u20133270. https:\/\/doi.org\/10.1161\/STROKEAHA.111.618801","journal-title":"Stroke"},{"issue":"1\u20133","key":"10161_CR33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ejphar.2008.08.002","volume":"596","author":"O Bj\u00f6rklund","year":"2008","unstructured":"Bj\u00f6rklund O, Shang M, Tonazzini I, Dar\u00e9 E, Fredholm BB (2008) Adenosine A1 and A3 receptors protect astrocytes from hypoxic damage. Eur J Pharmacol 596(1\u20133):6\u201313. https:\/\/doi.org\/10.1016\/j.ejphar.2008.08.002","journal-title":"Eur J Pharmacol"},{"key":"10161_CR34","unstructured":"Wanner I-B KA, Tajalli L, Holstein D, Liston T and Lechleiter J (2019) Cytoprotective Adora3 Agonist AST-004 Reduces Cell Death Rats of Traumatized Human Astrocytes., in National Neurotrauma Society:Pittsburgh, PA. A-80:Abstract A17\u201306"},{"issue":"8","key":"10161_CR35","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1002\/jnr.21071","volume":"84","author":"GJ Chen","year":"2006","unstructured":"Chen GJ, Harvey BK, Shen H, Chou J, Victor A, Wang Y (2006) Activation of adenosine A3 receptors reduces ischemic brain injury in rodents. J Neurosci Res 84(8):1848\u20131855. https:\/\/doi.org\/10.1002\/jnr.21071","journal-title":"J Neurosci Res"},{"issue":"2","key":"10161_CR36","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/jnc.14660","volume":"149","author":"A Martire","year":"2019","unstructured":"Martire A, Lambertucci C, Pepponi R, Ferrante A, Benati N, Buccioni M, Dal Ben D, Marucci G, Klotz KN, Volpini R, Popoli P (2019) Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia. J Neurochem 149(2):211\u2013230. https:\/\/doi.org\/10.1111\/jnc.14660","journal-title":"J Neurochem"},{"key":"10161_CR37","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/B978-0-12-801022-8.00013-1","volume":"119","author":"A Melani","year":"2014","unstructured":"Melani A, Pugliese AM, Pedata F (2014) Adenosine receptors in cerebral ischemia. Int Rev Neurobiol 119:309\u2013348. https:\/\/doi.org\/10.1016\/B978-0-12-801022-8.00013-1","journal-title":"Int Rev Neurobiol"},{"issue":"2","key":"10161_CR38","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0014-2999(94)90241-0","volume":"256","author":"DK Von Lubitz","year":"1994","unstructured":"Von Lubitz DK, Lin RC, Melman N, Ji XD, Carter MF, Jacobson KA (1994) Chronic administration of selective adenosine A1 receptor agonist or antagonist in cerebral ischemia. Eur J Pharmacol 256(2):161\u2013167. https:\/\/doi.org\/10.1016\/0014-2999(94)90241-0","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10161_CR39","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2174\/157015909789152209","volume":"7","author":"RL Williams-Karnesky","year":"2009","unstructured":"Williams-Karnesky RL, Stenzel-Poore MP (2009) Adenosine and stroke: maximizing the therapeutic potential of adenosine as a prophylactic and acute neuroprotectant. Curr Neuropharmacol 7(3):217\u2013227. https:\/\/doi.org\/10.2174\/157015909789152209","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"10161_CR40","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1023\/a:1023601007518","volume":"23","author":"IM Fedorova","year":"2003","unstructured":"Fedorova IM, Jacobson MA, Basile A, Jacobson KA (2003) Behavioral characterization of mice lacking the A3 adenosine receptor: sensitivity to hypoxic neurodegeneration. Cell Mol Neurobiol 23(3):431\u2013447. https:\/\/doi.org\/10.1023\/a:1023601007518","journal-title":"Cell Mol Neurobiol"},{"issue":"3","key":"10161_CR41","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nrd1983","volume":"5","author":"KA Jacobson","year":"2006","unstructured":"Jacobson KA, Gao ZG (2006) Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 5(3):247\u2013264. https:\/\/doi.org\/10.1038\/nrd1983","journal-title":"Nat Rev Drug Discov"},{"key":"10161_CR42","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.phrs.2013.08.002","volume":"76","author":"S Gessi","year":"2013","unstructured":"Gessi S, Merighi S, Stefanelli A, Fazzi D, Varani K, Borea PA (2013) A(1) and A(3) adenosine receptors inhibit LPS-induced hypoxia-inducible factor-1 accumulation in murine astrocytes. Pharmacol Res 76:157\u2013170. https:\/\/doi.org\/10.1016\/j.phrs.2013.08.002","journal-title":"Pharmacol Res"},{"issue":"2\u20133","key":"10161_CR43","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/s0014-2999(96)00901-6","volume":"320","author":"J Wang","year":"1997","unstructured":"Wang J, Drake L, Sajjadi F, Firestein GS, Mullane KM, Bullough DA (1997) Dual activation of adenosine A1 and A3 receptors mediates preconditioning of isolated cardiac myocytes. Eur J Pharmacol 320(2\u20133):241\u2013248. https:\/\/doi.org\/10.1016\/s0014-2999(96)00901-6","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"10161_CR44","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.1073\/pnas.95.12.6995","volume":"95","author":"BT Liang","year":"1998","unstructured":"Liang BT, Jacobson KA (1998) A physiological role of the adenosine A3 receptor: sustained cardioprotection. Proc Natl Acad Sci U S A 95(12):6995\u20136999. https:\/\/doi.org\/10.1073\/pnas.95.12.6995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1\u20132","key":"10161_CR45","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1023\/a:1007209321969","volume":"217","author":"N Safran","year":"2001","unstructured":"Safran N, Shneyvays V, Balas N, Jacobson KA, Nawrath H, Shainberg A (2001) Cardioprotective effects of adenosine A1 and A3 receptor activation during hypoxia in isolated rat cardiac myocytes. Mol Cell Biochem 217(1\u20132):143\u2013152. https:\/\/doi.org\/10.1023\/a:1007209321969","journal-title":"Mol Cell Biochem"},{"issue":"26","key":"10161_CR46","doi-asserted-by":"publisher","first-page":"8103","DOI":"10.1021\/jm050726b","volume":"48","author":"KA Jacobson","year":"2005","unstructured":"Jacobson KA, Gao ZG, Tchilibon S, Duong HT, Joshi BV, Sonin D, Liang BT (2005) Semi-rational design of (north)-methanocarba nucleosides as dual acting A(1) and A(3) adenosine receptor agonists: novel prototypes for cardioprotection. J Med Chem 48(26):8103\u20138107. https:\/\/doi.org\/10.1021\/jm050726b","journal-title":"J Med Chem"},{"key":"10161_CR47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.bcp.2019.01.022","volume":"163","author":"TC Wan","year":"2019","unstructured":"Wan TC, Tampo A, Kwok WM, Auchampach JA (2019) Ability of CP-532,903 to protect mouse hearts from ischemia\/reperfusion injury is dependent on expression of A(3) adenosine receptors in cardiomyoyctes. Biochem Pharmacol 163:21\u201331. https:\/\/doi.org\/10.1016\/j.bcp.2019.01.022","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10161_CR48","doi-asserted-by":"publisher","first-page":"H2780","DOI":"10.1152\/ajpheart.00411.2003","volume":"285","author":"WR Tracey","year":"2003","unstructured":"Tracey WR, Magee WP, Oleynek JJ, Hill RJ, Smith AH, Flynn DM, Knight DR (2003) Novel N6-substituted adenosine 5\u2019-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. Am J Physiol Heart Circ Physiol 285(6):H2780\u2013H2787. https:\/\/doi.org\/10.1152\/ajpheart.00411.2003","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"10","key":"10161_CR49","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1021\/acs.jmedchem.7b00291","volume":"60","author":"R Petrelli","year":"2017","unstructured":"Petrelli R, Scortichini M, Kachler S, Boccella S, Cerchia C, Torquati I, Del Bello F, Salvemini D, Novellino E, Luongo L, Maione S, Jacobson KA, Lavecchia A, Klotz KN, Cappellacci L (2017) Exploring the role of N(6)-substituents in potent dual acting 5\u2032-C-Ethyltetrazolyladenosine derivatives: synthesis, binding, functional assays, and antinociceptive effects in mice. J Med Chem 60(10):4327\u20134341. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00291","journal-title":"J Med Chem"},{"issue":"14","key":"10161_CR50","doi-asserted-by":"publisher","first-page":"5949","DOI":"10.1021\/jm4007966","volume":"56","author":"S Paoletta","year":"2013","unstructured":"Paoletta S, Tosh DK, Finley A, Gizewski ET, Moss SM, Gao ZG, Auchampach JA, Salvemini D, Jacobson KA (2013) Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain. J Med Chem 56(14):5949\u20135963. https:\/\/doi.org\/10.1021\/jm4007966","journal-title":"J Med Chem"},{"issue":"12","key":"10161_CR51","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1517\/13543780802497284","volume":"17","author":"E Elzein","year":"2008","unstructured":"Elzein E, Zablocki J (2008) A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs 17(12):1901\u20131910. https:\/\/doi.org\/10.1517\/13543780802497284","journal-title":"Expert Opin Investig Drugs"},{"key":"10161_CR52","unstructured":"Liston T, Manna L, Poe R, Korinek W, Roberts S and Lechleiter J (2024) Differentiating Properties that Increase the Potential of Cerebroprotectant AST-004 as a TBI Therapy, in Military Health System Research Symposium. Kissimmee, FL.  Abstract MHSRS-24\u201311777"},{"issue":"3","key":"10161_CR53","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.pharmthera.2009.03.002","volume":"122","author":"S Grimwood","year":"2009","unstructured":"Grimwood S, Hartig PR (2009) Target site occupancy: emerging generalizations from clinical and preclinical studies. Pharmacol Ther 122(3):281\u2013301. https:\/\/doi.org\/10.1016\/j.pharmthera.2009.03.002","journal-title":"Pharmacol Ther"},{"key":"10161_CR54","volume-title":"A pharmacology primer: techniques for more effective and strategic drug discovery","author":"TP Kenakin","year":"2014","unstructured":"Kenakin TP (2014) A pharmacology primer: techniques for more effective and strategic drug discovery. Academic Press, San Diego, California"},{"issue":"2","key":"10161_CR55","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0022-3565(24)37078-8","volume":"283","author":"PH Van Der Graaf","year":"1997","unstructured":"Van Der Graaf PH, Van Schaick EA, Math-ot RA, Ijzerman AP, Danhof M (1997) Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at Adenosine A1 receptors. J Pharmacol Exp Ther 283(2):809\u2013816","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"10161_CR56","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1161\/STROKEAHA.124.046688","volume":"55","author":"TE Liston","year":"2024","unstructured":"Liston TE, Holstein D, Solt D, Lozano D, Korinek WS, Lechleiter JD (2024) Lack of interactions between Alteplase\/Tenecteplase and the Adenosine A1R\/A3R agonist AST-004. Stroke 55(7):1923\u20131926. https:\/\/doi.org\/10.1161\/STROKEAHA.124.046688","journal-title":"Stroke"},{"issue":"3","key":"10161_CR57","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s11302-015-9459-2","volume":"11","author":"DK Tosh","year":"2015","unstructured":"Tosh DK, Padia J, Salvemini D, Jacobson KA (2015) Efficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3 Adenosine receptor agonist that protects against chronic neuropathic pain. Purinergic Signal 11(3):371\u2013387. https:\/\/doi.org\/10.1007\/s11302-015-9459-2","journal-title":"Purinergic Signal"},{"issue":"2","key":"10161_CR58","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.bcp.2015.07.007","volume":"97","author":"ZZ Fang","year":"2015","unstructured":"Fang ZZ, Tosh DK, Tanaka N, Wang H, Krausz KW, O\u2019Connor R, Jacobson KA, Gonzalez FJ (2015) Metabolic mapping of A3 Adenosine receptor agonist MRS5980. Biochem Pharmacol 97(2):215\u2013223. https:\/\/doi.org\/10.1016\/j.bcp.2015.07.007","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"10161_CR59","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1161\/strokeaha.124.047207","volume":"55","author":"LM Manna","year":"2024","unstructured":"Manna LM, Hernandez J, Hunt DE, Lakner G, Matson MA, Poe RB, Korinek WS, Lancey RA, Liston TE (2024) First-in-human phase I clinical trial of the Adenosine A1R\/A3R agonist AST-004 in healthy subjects. Stroke 55(12):2795\u20132803. https:\/\/doi.org\/10.1161\/strokeaha.124.047207","journal-title":"Stroke"},{"key":"10161_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27123680","author":"P Fishman","year":"2022","unstructured":"Fishman P (2022) Drugs targeting the A3 Adenosine receptor: human clinical study data. Molecules. https:\/\/doi.org\/10.3390\/molecules27123680","journal-title":"Molecules"}],"container-title":["Purinergic Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-026-10161-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11302-026-10161-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-026-10161-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T05:06:40Z","timestamp":1782364000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11302-026-10161-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10161"],"URL":"https:\/\/doi.org\/10.1007\/s11302-026-10161-7","relation":{},"ISSN":["1573-9538","1573-9546"],"issn-type":[{"value":"1573-9538","type":"print"},{"value":"1573-9546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"18 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All in vivo preclinical studies described in this article were conducted following review and approval by relevant IACUC committees. All clinical studies described were conducted in accordance with applicable regulatory requirements and were reviewed and approved by the relevant national regulatory authorities and independent ethics committees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"TEL and WSK are employees of Astrocyte Pharmaceuticals Inc. with multiple patents.  JDL is a cofounder of Astrocyte Pharmaceuticals Inc. with multiple patents.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}